BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15857847)

  • 1. Does the concurrent use of anthracycline and granulocyte colony-stimulating factor influence the risk of secondary leukaemia in breast cancer women?
    Di Cosimo S; Ferretti G; Papaldo P; Carlini P; Fabi A; Ruggeri EM; Alimonti A; Nardoni C; Cognetti F
    Ann Oncol; 2005 Jul; 16(7):1209-10. PubMed ID: 15857847
    [No Abstract]   [Full Text] [Related]  

  • 2. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Granulocyte colony-stimulating factor: key (f)actor or innocent bystander in the development of secondary myeloid malignancy?
    Touw IP; Bontenbal M
    J Natl Cancer Inst; 2007 Feb; 99(3):183-6. PubMed ID: 17284707
    [No Abstract]   [Full Text] [Related]  

  • 4. Granulocyte colony-stimulating factor and severe aplastic anemia.
    Alter BP; Rosenberg PS
    Blood; 2007 May; 109(10):4589; author reply 4589-90. PubMed ID: 17483301
    [No Abstract]   [Full Text] [Related]  

  • 5. Lineage-specific hematopoietic growth factors.
    Ferretti G; Papaldo P; Cognetti F
    N Engl J Med; 2006 Aug; 355(5):526; author reply 527. PubMed ID: 16885561
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute myeloid leukaemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Ferretti G; Papaldo P
    Breast Cancer Res Treat; 2008 May; 109(1):187-8. PubMed ID: 17616805
    [No Abstract]   [Full Text] [Related]  

  • 7. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.
    Bergh J; Wiklund T; Erikstein B; Lidbrink E; Lindman H; Malmström P; Kellokumpu-Lehtinen P; Bengtsson NO; Söderlund G; Anker G; Wist E; Ottosson S; Salminen E; Ljungman P; Holte H; Nilsson J; Blomqvist C; Wilking N
    Lancet; 2000 Oct; 356(9239):1384-91. PubMed ID: 11052580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myelodysplastic syndrome and acute myeloid leukemia secondary to mitolactol treatment in patients with breast cancer.
    Bennett JM; Troxel AB; Gelman R; Falkson G; Coccia-Portugal MD; Dreicer R; Tormey DC; Rushing D
    J Clin Oncol; 1994 Apr; 12(4):874-5. PubMed ID: 8151329
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term complications of cancer chemotherapy.
    Pedersen-Bjergaard J
    J Clin Oncol; 1995 Jul; 13(7):1534-6. PubMed ID: 7602341
    [No Abstract]   [Full Text] [Related]  

  • 10. Secondary leukaemia after MMM combined modality therapy for breast carcinoma.
    Philpott NJ; Bevan DH; Gordon-Smith EC
    Lancet; 1993 May; 341(8855):1289. PubMed ID: 8098437
    [No Abstract]   [Full Text] [Related]  

  • 11. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.
    Le Deley MC; Suzan F; Cutuli B; Delaloge S; Shamsaldin A; Linassier C; Clisant S; de Vathaire F; Fenaux P; Hill C
    J Clin Oncol; 2007 Jan; 25(3):292-300. PubMed ID: 17159192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience.
    Smith RE; Bryant J; DeCillis A; Anderson S;
    J Clin Oncol; 2003 Apr; 21(7):1195-204. PubMed ID: 12663705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients.
    Rosenstock AS; Niu J; Giordano SH; Zhao H; Wolff AC; Chavez-MacGregor M
    Cancer; 2018 Mar; 124(5):899-906. PubMed ID: 29236294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of advanced, refractory breast cancer with alternating docetaxel and epirubicin/cyclophosphamide plus human granulocyte colony-stimulating factor.
    Kwasny W; Kornek G; Haider K; Valencak J; Ulrich-Pur H; Penz M; Lang F; Depisch D; Scheithauer W
    Breast Cancer Res Treat; 2000 Oct; 63(3):235-41. PubMed ID: 11110057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.
    Kröger N; Damon L; Zander AR; Wandt H; Derigs G; Ferrante P; Demirer T; Rosti G; ; ;
    Bone Marrow Transplant; 2003 Dec; 32(12):1153-7. PubMed ID: 14647269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can granulocyte-colony stimulating factor worsen anemia?
    Dang C; Hudis C
    J Clin Oncol; 2006 Jul; 24(19):2985-6. PubMed ID: 16769981
    [No Abstract]   [Full Text] [Related]  

  • 17. The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. An NSABP pilot study in patients with metastatic or high-risk primary breast cancer. National Surgical Adjuvant Breast and Bowel Project.
    Mamounas EP; Anderson S; Wickerham DL; Clark R; Stoller R; Hamm JT; Stewart JA; Bear HD; Glass AG; Bornstein R
    Am J Clin Oncol; 1994 Oct; 17(5):374-81; discussion 382. PubMed ID: 7522393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma.
    Saso R; Kulkarni S; Mitchell P; Treleaven J; Swansbury GJ; Mehta J; Powles R; Ashley S; Kuan A; Powles T
    Br J Cancer; 2000 Jul; 83(1):91-4. PubMed ID: 10883674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients.
    Bernard-Marty C; Mano M; Paesmans M; Accettura C; Munoz-Bermeo R; Richard T; Kleiber K; Cardoso F; Lobelle JP; Larsimont D; Piccart MJ; Di Leo A
    Ann Oncol; 2003 May; 14(5):693-8. PubMed ID: 12702521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High incidence of therapy-related myelodysplasia and acute leukaemia in general haematology clinic patients treated with fludarabine and cyclophosphamide for indolent lymphoproliferative disorders.
    Bowcock SJ; Rassam SM; Lim Z; Ward SM; Ryali MM; Mufti GJ
    Br J Haematol; 2006 Jul; 134(2):242-3. PubMed ID: 16846486
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.